N
News Analysis
tickerreport.com

www.tickerreport.com ·

Positive

Hc Wainwright Issues Optimistic Estimate for Vtvt Earnings

ChronicdiseaseNon Communicable Disease And …DiseaseHealth

All NewsRead the full story on tickerreport.com

The full article is on the original publisher site. This page only shows the headline and a very short excerpt.

AI insight

AI-generated

Analyst estimate revision for vTv Therapeutics (VTVT), a clinical-stage biotech. No product revenue or commercial mechanism described; EPS improvement driven by non-operational items or milestone payments. Weak commercial signal — no drug approval, supply chain, or pricing power change.

Signals our AI researcher identified

Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.

  • HC Wainwright raised Q2 2026 EPS estimate for VTVT from ($0.64) to ($0.51).
  • Full-year 2026 EPS estimate is ($2.28).
  • Q1 2026 actual EPS was $1.65 vs consensus $0.21, revenue $36.84M.
  • Market cap $139.83M, consensus price target $53.00.

About the publisher

tickerreport.com is one of the en-language news outlets that News Analysis aggregates. Coverage from this source appears in our global feed alongside the publisher's own reporting.

Topic context

tickerreport.com files this story under "chronicdisease" in the GDELT knowledge graph. News Analysis surfaces coverage based on the same open classification taxonomy.

Hc Wainwright Issues Optimistic Estimate for Vtvt Earnings — News Analysis